Rhythm Pharmaceuticals RYTM

$ 52.55 7.21%

Quarterly report 2024-Q2
added 08-06-2024

Rhythm Pharmaceuticals Balance Sheet 2011-2024 | RYTM

Annual Balance Sheet Rhythm Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-58.8 M	-126 M	-56.7 M	-	-58.7 M	-49.5 M	-34.2 M	-6.54 M	-34.9 M	-	-7.36 M	-11.8 M	-
Long Term Debt	490 K	1.26 M	1.94 M	-	-	-	-	-	-	-	-	-	-
Long Term Debt Current	770 K	684 K	606 K	535 K	472 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	3.09 M	372 K	228 K	311 K	-	-	72.6 M	52.7 M	-
Total Current Liabilities	55.2 M	39.8 M	43.4 M	18 M	24.4 M	13.6 M	6.72 M	4.73 M	-	-	-	-	-
Total Liabilities	163 M	118 M	45.4 M	20.5 M	27.5 M	14 M	6.95 M	5.04 M	5.27 M	-	75.6 M	55.2 M	-
Deferred Revenue	1.29 M	1.43 M	7 M	-	-	-	-	-	249 K	-	-	-	-
Retained Earnings	-895 M	-710 M	-529 M	-459 M	-325 M	-185 M	-110 M	-76.5 M	-50.7 M	-	-58.4 M	-37 M	-
Total Assets	333 M	382 M	330 M	187 M	309 M	260 M	152 M	12.3 M	37.3 M	-	18.2 M	18.9 M	-
Cash and Cash Equivalents	60.1 M	128 M	59.2 M	101 M	62.3 M	49.5 M	34.2 M	6.54 M	-	-	-	-	-
Book Value	170 M	264 M	284 M	167 M	281 M	246 M	145 M	7.3 M	32 M	-	-57.5 M	-36.3 M	-
Total Shareholders Equity	170 M	264 M	284 M	167 M	281 M	246 M	145 M	-32.7 M	-8 M	-358 K	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Rhythm Pharmaceuticals

	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	3.3 M	284 K	490 K	692 K	888 K	1.08 M	1.26 M	73 M	-	1.78 M	1.94 M	2.1 M	2.26 M	2.41 M	2.55 M	2.55 M	2.55 M	2.55 M	3.09 M	3.09 M	3.09 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	202 M	197 M	163 M	157 M	128 M	126 M	118 M	108 M	-	49.1 M	45.4 M	33.6 M	36.7 M	41.3 M	20.5 M	20.5 M	20.5 M	20.5 M	27.5 M	27.5 M	27.5 M	27.5 M	14 M	14 M	14 M	14 M	6.95 M	6.95 M	6.95 M	6.95 M	5.04 M	5.04 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	1.29 M	1.29 M	1.29 M	1.29 M	1.29 M	1.43 M	1.43 M	1.76 M	-	9.44 M	7 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.07 B	-1.04 B	-895 M	-853 M	-809 M	-762 M	-710 M	-668 M	-	-582 M	-529 M	-486 M	-451 M	-416 M	-459 M	-459 M	-459 M	-459 M	-325 M	-325 M	-325 M	-325 M	-185 M	-185 M	-185 M	-185 M	-110 M	-110 M	-110 M	-110 M	-76.5 M	-76.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	382 M	259 M	333 M	354 M	310 M	346 M	382 M	390 M	-	285 M	330 M	356 M	388 M	422 M	187 M	187 M	187 M	187 M	309 M	309 M	309 M	309 M	260 M	260 M	260 M	260 M	152 M	152 M	152 M	152 M	12.3 M	12.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	162 M	53.4 M	60.1 M	64.6 M	116 M	110 M	128 M	185 M	-	78.5 M	59.2 M	92.4 M	69.3 M	87.3 M	101 M	101 M	101 M	101 M	62.3 M	62.3 M	62.3 M	62.3 M	49.5 M	49.5 M	49.5 M	49.5 M	34.2 M	34.2 M	34.2 M	34.2 M	6.54 M	6.54 M	-	-	34.9 M	-	-	-	152 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	179 M	61.6 M	170 M	197 M	182 M	220 M	264 M	281 M	-	236 M	284 M	322 M	352 M	381 M	167 M	167 M	167 M	167 M	281 M	281 M	281 M	281 M	246 M	246 M	246 M	246 M	145 M	145 M	145 M	145 M	7.3 M	7.3 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	39.3 M	61.6 M	170 M	197 M	182 M	220 M	264 M	281 M	196 M	236 M	284 M	322 M	352 M	381 M	167 M	167 M	167 M	167 M	281 M	281 M	281 M	281 M	246 M	246 M	246 M	246 M	145 M	145 M	145 M	145 M	-32.7 M	-32.7 M	-	-	-8 M	-	-	-	-358 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency